MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease
April 05, 2023 08:35 ET
|
Advantage Therapeutics Inc.
MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...
Underdog Pharmaceuticals Awarded ‘Innovation Passport’ by UK Regulators
September 08, 2021 11:00 ET
|
Underdog Pharmaceuticals Inc.
MOUNTAIN VIEW, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Underdog Pharmaceuticals, Inc. (Underdog), a pre-clinical stage pharmaceutical company focusing on the treatment and reversal of age-related...